Erin Gillespie, MD MPH Rupesh Kotecha Simon Powell C. Jillian Tsai, MD, PhD Jonathan Yang Excellent editorial Matthew P Deek Dr. Tran & Salma Jabbour
Eval for Met Directed Tx:
•Oligo Mets
•Oligo Prog Dz
•Proph High Risk Dz
•Symptomatic Dz
 
doi.org/10.1200/jco.23…

Phuoc Tran with the Mentorship Award!! Well deserved—such a fantastic champion of others in the field 🙌🏼👏🏻
Kekoa Taparra, MD, PhD Sophia Kamran, MD Rana McKay NRG Oncology ASTRO #ASTRO23

Congratulations to Rutgers Radiation Oncology faculty, Dr. Deek Matthew P Deek and chief resident, Dr. Kim Jongmyung Kim, MD PhD for being recognized by ASTRO for their contributions to the advancement of our field. RutgersCancerInstNJ Rutgers RWJMedSchool Rutgers New Jersey Medical School RWJBarnabas

Strong #radonc representation at the #PCFAcademy 💪🏽& thrilled to put together an all ⭐️ RT session. Excellent discussions & ideas to improve treatments & outcomes for our PCa pts. “RT is a powerful anti-cancer agent.” Let’s further harness it for the future: CHARGE!

Multi-institutional analysis of metastasis directed therapy with or without ADT in oligometastatic castration-sensitive #ProstateCancer . Presented by Matthew P Deek RWJBarnabas. #AUA23 written coverage by Zach Klaassen Georgia Cancer Center > bit.ly/3oXLQ7B Amer. Urol. Assn.

Please come and join our faculty Matthew P Deek presenting his study on oligometasis #ASTRO2022 ASTRO Rutgers Radiation Oncology RutgersCancerInstNJ Rutgers RWJMedSchool Rutgers New Jersey Medical School

SBRT for oligometastasis: GUst do it? Check out our oncology scan in IJROBP - The Red Journal with oligomet experts Alejandro (Ale) Berlin Dr. David Palma Matthew P Deek C. Jillian Tsai, MD, PhD Shankar Siva Piet Ost authors.elsevier.com/a/1fvZq1Hx52CH… . Thank you Alejandro (Ale) Berlin Sue Yom IJROBP - The Red Journal for the opportunity!

🚀 #JCO #RapidCommunication : STOMP & ORIOLE show improved progression-free survival w metastsis driven therapy over observation in oligometastatic #ProstateCancer
🎯 Largest benefit for patients harboring a high-risk mutation #PCSM Matthew P Deek Piet Ost fal.cn/3s1ch

Enjoyed working with Piet Ost Kim Van der Eecken and Phu Tran on this. Hopefully we can continue to better understand the biology of oligometastasis to personalize treatment. RutgersCancerInstNJ

Congratulations to our PGY-4 resident Jongmyung Kim, MD PhD Rutgers Radiation Oncology RutgersCancerInstNJ for his study on genetic alterations in pancreatic cancer being accepted for presenting at Radiation Research Society annual meeting this year. This study was mentored by our faculty Matthew P Deek and Salma Jabbour

Counting mets is currently used for deciding to debulk, to give chemo (NCCN&ASCO only), and triplet (PEACE1). Will the detection of genomic mutations (tp53, DNA-DSB, WNT) replace it? Nick James Piet Ost Alejandro (Ale) Berlin Emmanuel Antonarakis AttardLab europeanurology.com/article/S0302-…

Definitions of disease burden across the spectrum of #mCSPC : Comparison by disease outcomes & genomics. #BeyondTheAbstract on UroToday > bit.ly/3u9yG8a Prostate Cancer and Prostatic Diseases Matthew P Deek Amar Kishan AttardLab Anis Hamid Ashley Ross MD PhD Piet Ost Emmanuel Antonarakis Felix Feng

Definitions of disease burden across the spectrum of #mCSPC : Comparison by disease outcomes & genomics. #BeyondTheAbstract on UroToday > bit.ly/3u9yG8a Prostate Cancer and Prostatic Diseases Matthew P Deek Amar Kishan AttardLab Anis Hamid Ashley Ross MD PhD Piet Ost Emmanuel Antonarakis Felix Feng

-BRPC/LAPC, n=132
-SBRT ☢️, 33 Gy/5 fx
-Dose to vertebral bodies (VB) and spleen ➡️ G2+ lymphopenia and ⬇️ALC
-Thresholds: VB V15≥5.84%, VB V2.5≥48.4%, spleen V10≥4.17%
-prior data shows lymphopenia ➡️ ❌ outcomes
- ➡️VB and spleen as OARs?

ro-journal.biomedcentral.com/articles/10.11…

Congratulations to Bruce G. Haffty, MD, 2022 RSNA President! Dr. Haffty plans to focus on expanding RSNA’s profile in the broader medical community and to promote the value of radiology to patients & partners in health care delivery. bit.ly/3D9GBDa #RSNA21 Bruce Haffty

Is there a Clinical Utility for Tissue- and Blood-derived Genomic Biomarkers in metastatic hormone-sensitive #ProstateCancer ? Check out our systematic review on genomic alterations in mHSPC reported in European Urology Oncology: authors.elsevier.com/a/1e5cE9Cfv-qB…

[1/7]

Is metastasis-directed therapy the wave of the future in oligo-mCRPC? Presentation by Matthew P Deek RutgersCancerInstNJ. #ASTRO21 written coverage by Zach Klaassen Georgia Cancer Center on UroToday > bit.ly/3pRYNP3 ASTRO

#EAU21 is over, now it's time for another European Urology Oncology #SoMe Award. This month's winner is...

Metastasis-directed Therapy Prolongs Efficacy of Systemic Therapy & Improves Clinical Outcomes in Oligoprogressive CRPC

euoncology.europeanurology.com/article/S2588-…

Congrats to Matthew P Deek Kekoa Taparra, MD, PhD

The mutational landscape of metastatic castration-sensitive #ProstateCancer . Matthew P Deek & Phuoc Tran, MD, PhD Johns Hopkins Medicine join Charles Ryan Masonic Cancer Center, University of Minnesota to discuss their recent paper published in European Urology. #WatchNow on UroToday > bit.ly/2ZEXMvd

The mutational landscape of metastatic castration-sensitive #ProstateCancer . Matthew P Deek & Phuoc Tran, MD, PhD Johns Hopkins Medicine join Charles Ryan Masonic Cancer Center, University of Minnesota to discuss their recent paper published in European Urology. #WatchNow on UroToday > bit.ly/2ZEXMvd